Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 19/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 17/20 | 1.00 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 1.00 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 1.00 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13034168 | 0.95 | L3MBTL3 (0.91) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL14529142 | 0.95 | L3MBTL3 (0.91) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL14529143 | 0.92 | L3MBTL3 (0.84) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL23682730 | 0.91 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL13034163 | 0.89 | L3MBTL3 (0.80) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL23682947 | 0.89 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL14528665 | 0.88 | L3MBTL3 (0.78) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL13034196 | 0.86 | L3MBTL3 (0.74) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL21776913 | 0.86 | L3MBTL3 (0.75) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL13034197 | 0.85 | L3MBTL3 (0.72) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | L3MBTL3 3097/4885L3MBTL1 3195/4885MBTD1 773/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | L3MBTL3 518/4885L3MBTL1 228/4885MBTD1 2125/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | L3MBTL3 518/4885L3MBTL1 228/4885MBTD1 2125/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | L3MBTL3 1221/4885L3MBTL1 737/4885MBTD1 3067/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | L3MBTL3 1368/4885L3MBTL1 718/4885MBTD1 2460/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | L3MBTL3 372/4885L3MBTL1 173/4885MBTD1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.